Cytokinetics, Inc. (CYTK)

[Solantey]

C.E.O.'s comments from BENEFIT-ALS conference call:

"We also know that this study did hit on pre-specified secondary analyses that are deemed important, clinically meaningful, and predictive of disease progression and survival. With that, we have great responsibilities, as well. We operate with great responsibilities across this program and as a company. Next week, we’ll talk financially. Cytokinetics has an earnings call scheduled for Tuesday, May 6, and at that time we’ll update on the financial metrics of the Company, our cash, number of months of forward burn, expected milestone payments, and other things that read on financial measures of the companies viability and sustainability and especially we are please that the other programs are advancing to key milestone as fully funded by our partner."

Stay tuned for news on Tuesday after the close.

Substantially more upside than downside at the current price.

All IMHO.